Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
1. EXAS reported a Q1 EPS loss of 21 cents, better than expected. 2. Quarterly sales of $706.78 million beat consensus by 11%. 3. Company raised 2025 sales guidance to $3.07-$3.12 billion. 4. Analysts remain positive, citing potential for future growth. 5. Shares rose 11.3% during pre-market trading following the news.